Togaviridae Disease Overview

Save information for later
Sign Up

Learn About Togaviridae Disease

What is the definition of Togaviridae Disease?
Togaviridae disease is a term used to describe a family of viruses grouped into two categories: Alphavirus and Rubivirus. Alphaviruses are spread primarily by mosquitoes and other insects, spiders, or crustaceans to humans and cause arthritis and encephalitis. Rubivirus, commonly known as Rubella, causes the childhood disease and is transmitted through airborne aerosol droplets.
What are the symptoms of Togaviridae Disease?
Symptoms of alphaviruses can include flu-like symptoms, fever, arthritis, headache, pain, muscle pain, rash, encephalitis, and/or other further complications. Symptoms of Rubella include fever, joint pain, headache, rash, and swollen glands (lymph nodes).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Togaviridae Disease?
Treatment for Togaviridae disease is mainly supportive care that addresses symptoms or complications. Other methods of prevention include vector-control and protecting against mosquito bites.
Who are the top Togaviridae Disease Local Doctors?
Distinguished in Togaviridae Disease
Tyler M. Sharp
Distinguished in Togaviridae Disease
Tyler M. Sharp
Dengue Branch, 
San Juan, PR 
 (30.5 mi)

Tyler Sharp practices in San Juan, Puerto Rico. Sharp and is rated as a Distinguished expert by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Zika Virus Disease, and Leptospirosis.

Distinguished in Togaviridae Disease
Michael A. Johansson
Distinguished in Togaviridae Disease
Michael A. Johansson
Dengue Branch, 
San Juan, PR 
 (30.5 mi)

Michael Johansson practices in San Juan, Puerto Rico. Johansson and is rated as a Distinguished expert by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Zika Virus Disease, and Togaviridae Disease.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Togaviridae Disease
Tingting J. Hu
Experienced in Togaviridae Disease
Tingting J. Hu
PR China, 
Shanghai, PR 
 (11.5 mi)

Tingting Hu practices in Shanghai, Puerto Rico. Hu and is rated as an Experienced expert by MediFind in the treatment of Togaviridae Disease. Their top areas of expertise are Comedones, Togaviridae Disease, Epidermoid Cyst, and Acne.

View All Doctors
What are the latest Togaviridae Disease Clinical Trials?
A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Double Blind, Randomized, Placebo-Controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated Chikungunya Virus Vaccine, HydroVax-005 CHIKV, in Healthy Adults
A Double Blind, Randomized, Placebo-Controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated Chikungunya Virus Vaccine, HydroVax-005 CHIKV, in Healthy Adults
Enrollment Status: Recruiting
Publish Date: November 05, 2024
Intervention Type: Other, Biological
Study Phase: Phase 1

Summary: This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day 29 in up to 48 healthy adults healthy adults ≥ 18 and \< 50 years of age. The primary objective is to assess the safety and reactogenicity of the HydroVax-005 CHIKV vaccin...

View All Clinical Trials